

Resource Summary Report

Generated by [dkNET](#) on Aug 1, 2026

InVivoMab anti-mouse NK1.1

RRID:AB_1107737

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0036, RRID:AB_1107737)

Antibody Information

URL: http://antibodyregistry.org/AB_1107737

Proper Citation: (Bio X Cell Cat# BE0036, RRID:AB_1107737)

Target Antigen: NK1.1

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow Cytometry, in vivo Cell Specific Depletion

Antibody Name: InVivoMab anti-mouse NK1.1

Description: This monoclonal targets NK1.1

Target Organism: mouse

Clone ID: clone PK136

Antibody ID: AB_1107737

Vendor: Bio X Cell

Catalog Number: BE0036

Alternative Catalog Numbers: BE0036-25MG, BE0036-100MG, BE0036-5MG, BE0036-50MG, BE0036-1MG

Record Creation Time: 20260114T193114+0000

Record Last Update: 20260706T190413+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMab anti-mouse NK1.1.

No alerts have been found for InVivoMab anti-mouse NK1.1.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 102 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Heaton AR, et al. (2026) Divergent role of CD8 T cells with distinct metabolic phenotypes during curative radio-immunotherapy in hot versus cold tumors. bioRxiv : the preprint server for biology.

Xiang H, et al. (2026) Predominant mutated non-canonical tumor-specific antigens identified by proteogenomics demonstrate immunogenicity and tumor suppression in CRC. Cell genomics, 6(1), 101062.

Avanessian SC, et al. (2026) IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy. Cancer immunology research, 14(1), 122.

Qian J, et al. (2025) A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis. Cancer cell, 43(8), 1512.

Garofalo S, et al. (2025) Platelets tune fear memory in mice. Cell reports, 44(2), 115261.

Niu D, et al. (2025) Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors. Cell reports. Medicine, 6(10), 102413.

Shimizu K, et al. (2025) Distinct TAM subset with cross-dressing capability determines the bifurcation of tumor immunity. Cell reports, 44(6), 115800.

Champiat S, et al. (2025) Nanrilkefusp alfa (SOT101), an IL-15 receptor ?? superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. Cell reports. Medicine, 6(2), 101967.

Hai Y, et al. (2025) An immunometabolic prodrug strategy overcomes DHODH inhibitor resistance in refractory melanoma. Journal of experimental & clinical cancer research : CR, 44(1), 306.

da Silva Bortoleti BT, et al. (2025) A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors. Nature communications, 16(1), 9915.

Wang Y, et al. (2025) Inhibition of tumor cell macropinocytosis driver DHODH reverses immunosuppression and overcomes anti-PD1 resistance. *Immunity*.

Wang R, et al. (2025) An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B β 1/2 shedding. *Cell reports. Medicine*, 6(3), 101981.

Jardim C, et al. (2025) Sustained Macrophage Reprogramming Is Required for CD8+ T cell-Dependent Long-Term Tumor Eradication. *Cancer immunology research*, 13(8), 1207.

Ahn JJ, et al. (2025) Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity. *Cell reports. Medicine*, 6(8), 102257.

Bian Q, et al. (2025) Maternal natural killer cells drive neuroimmune disorders in offspring through aberrant secretion of extracellular granzyme B. *Immunity*, 58(6), 1502.

Yamane K, et al. (2025) ULBP2 Promotes Tumor Progression by Suppressing NKG2D-Mediated Anti-Tumor Immunity. *International journal of molecular sciences*, 26(7).

Zhang Y, et al. (2025) Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance. *Cell*, 188(24), 6754.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. *Cell reports*, 45(1), 116757.

Wei H, et al. (2025) AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity. *Cell metabolism*, 37(5), 1103.

Lecky DAJ, et al. (2025) Interferon- γ and IL-27 positively regulate type 1 regulatory T cell development during adaptive tolerance. *iScience*, 28(5), 112308.